	US 12,342,842 B2
	Preparation for use in enhancing formation of short-chain fatty acids (SCFAs)
Bodo Speckmann, Kahl (DE); Michael Schwarm, Alzenau (DE); Ines Ochrombel, Essen (DE); and Stefan Pelzer, Gütersloh (DE)
Assigned to Evonik Operations GmbH, Essen (DE)
Appl. No. 17/612,755
Filed by Evonik Operations GmbH, Essen (DE)
PCT Filed May 18, 2020, PCT No. PCT/EP2020/063794 § 371(c)(1), (2) Date Nov. 19, 2021, PCT Pub. No. WO2020/234230, PCT Pub. Date Nov. 26, 2020.
Claims priority of application No. 19176061 (EP), filed on May 23, 2019.
Prior Publication US 2022/0312816 A1, Oct. 6, 2022
Int. Cl. A23L 33/12 (2016.01); A23C 9/13 (2006.01); A23C 19/093 (2006.01); A23L 33/175 (2016.01); A61K 9/00 (2006.01); A61K 31/202 (2006.01)

CPC A23L 33/12 (2016.08) [A23C 9/1315 (2013.01); A23C 19/093 (2013.01); A23L 33/175 (2016.08); A61K 9/0053 (2013.01); A61K 31/202 (2013.01)]

17 Claims

1. A colonic preparation, comprising:

an omega-3 fatty acid salt having an organic counter ion selected from the group consisting of lysine, arginine, ornithine, choline, and a combination thereof; and

a colon-specific delivery system selected from the group consisting of a delivery system comprising a coating with a pH dependent polymer, a delivery system comprising a coating with a pH independent biodegradable polymer, and a delivery system based on a metabolic activity of a colonic bacteria,

wherein the omega-3 fatty acid is selected from the group consisting of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and

wherein the preparation is a powder having a mean particle size of 1 μm or less.